Shandong Keyuan Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Shandong Keyuan Pharmaceutical has been growing earnings at an average annual rate of 13.2%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 10.5% per year. Shandong Keyuan Pharmaceutical's return on equity is 4.9%, and it has net margins of 14.2%.
Key information
13.2%
Earnings growth rate
4.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 10.5% |
| Return on equity | 4.9% |
| Net Margin | 14.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shandong Keyuan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 470 | 66 | 108 | 45 |
| 31 Dec 23 | 448 | 77 | 100 | 44 |
| 30 Sep 23 | 449 | 89 | 91 | 41 |
| 30 Jun 23 | 443 | 91 | 86 | 32 |
| 31 Mar 23 | 454 | 96 | 69 | 30 |
| 01 Jan 23 | 443 | 91 | 57 | 27 |
| 01 Jan 22 | 421 | 78 | 63 | 24 |
| 31 Dec 20 | 367 | 69 | 71 | 28 |
| 31 Dec 19 | 311 | 30 | 62 | 31 |
| 30 Sep 19 | 301 | 46 | 55 | 17 |
| 30 Jun 19 | 265 | 53 | 26 | 12 |
| 31 Mar 19 | 261 | 44 | 34 | 11 |
| 31 Dec 18 | 271 | 20 | 56 | 11 |
| 30 Sep 18 | 266 | 31 | 46 | 8 |
| 30 Jun 18 | 260 | 34 | 41 | 7 |
| 31 Mar 18 | 249 | 46 | 29 | 0 |
| 31 Dec 17 | 239 | 44 | 27 | 7 |
| 30 Sep 17 | 218 | 40 | 26 | 5 |
| 30 Jun 17 | 196 | 36 | 25 | 2 |
| 31 Mar 17 | 183 | 32 | 27 | 0 |
| 31 Dec 16 | 180 | 33 | 24 | 0 |
| 30 Sep 16 | 167 | 29 | 24 | 0 |
| 30 Jun 16 | 155 | 25 | 23 | 0 |
| 31 Mar 16 | 139 | 20 | 21 | 0 |
| 31 Dec 15 | 123 | 14 | 19 | 0 |
| 31 Dec 14 | 133 | 9 | 16 | 0 |
| 31 Dec 13 | 133 | 1 | 22 | 0 |
Quality Earnings: 301281 has a high level of non-cash earnings.
Growing Profit Margin: 301281's current net profit margins (14.2%) are lower than last year (21.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301281's earnings have grown by 13.2% per year over the past 5 years.
Accelerating Growth: 301281's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301281 had negative earnings growth (-30.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 301281's Return on Equity (4.9%) is considered low.